We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Fig 2.

Fig 2. From: Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer.

Maximum percent change in prostate-specific antigen (PSA) from baseline in patients.

Yang-Min Ning, et al. J Clin Oncol. 2010 April 20;28(12):2070-2076.
2.
Fig 3.

Fig 3. From: Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer.

Kaplan-Meier analysis of (A) progression-free survival and (B) overall survival for all patients on study.

Yang-Min Ning, et al. J Clin Oncol. 2010 April 20;28(12):2070-2076.
3.
Fig 4.

Fig 4. From: Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer.

Changes in circulating apoptotic endothelial cells (CAECs) at 6 weeks. PSA, prostate-specific antigen.

Yang-Min Ning, et al. J Clin Oncol. 2010 April 20;28(12):2070-2076.
4.
Fig 1.

Fig 1. From: Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer.

Efficacy of therapeutic agents in PC3 xenograft mouse models following vehicle (solid circle), docetaxel (solid square), thalidomide (solid triangle), or bevacizumab (inverted solid triangle) alone; a dual combination of docetaxel and thalidomide (solid diamond), docetaxel and bevacizumab (open circle), thalidomide and bevacizumab (open square); and a combination of docetaxel, thalidomide, and bevacizumab (open triangle). Values are means from five to eight mice. Doc, docetaxel; Thal, thalidomide; BV, bevacizumab.

Yang-Min Ning, et al. J Clin Oncol. 2010 April 20;28(12):2070-2076.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk